XFOR vs. VCXB, CLLS, CRDF, VXRT, CGEN, CRDL, GNFT, ADVM, VIGL, and ELEV
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include 10X Capital Venture Acquisition Corp. III (VCXB), Cellectis (CLLS), Cardiff Oncology (CRDF), Vaxart (VXRT), Compugen (CGEN), Cardiol Therapeutics (CRDL), Genfit (GNFT), Adverum Biotechnologies (ADVM), Vigil Neuroscience (VIGL), and Elevation Oncology (ELEV). These companies are all part of the "biological products, except diagnostic" industry.
10X Capital Venture Acquisition Corp. III (NYSE:VCXB) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.
10X Capital Venture Acquisition Corp. III has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
X4 Pharmaceuticals' return on equity of 0.00% beat 10X Capital Venture Acquisition Corp. III's return on equity.
13.3% of 10X Capital Venture Acquisition Corp. III shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 71.5% of 10X Capital Venture Acquisition Corp. III shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
X4 Pharmaceuticals has a consensus target price of $3.00, suggesting a potential upside of 236.32%. Given 10X Capital Venture Acquisition Corp. III's higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than 10X Capital Venture Acquisition Corp. III.
X4 Pharmaceuticals received 71 more outperform votes than 10X Capital Venture Acquisition Corp. III when rated by MarketBeat users.
In the previous week, X4 Pharmaceuticals had 4 more articles in the media than 10X Capital Venture Acquisition Corp. III. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 1 mentions for 10X Capital Venture Acquisition Corp. III. X4 Pharmaceuticals' average media sentiment score of 1.68 beat 10X Capital Venture Acquisition Corp. III's score of 0.10 indicating that 10X Capital Venture Acquisition Corp. III is being referred to more favorably in the media.
Summary
X4 Pharmaceuticals beats 10X Capital Venture Acquisition Corp. III on 6 of the 11 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
